Search

Your search keyword '"Ibata, Hidenori"' showing total 31 results

Search Constraints

Start Over You searched for: Author "Ibata, Hidenori" Remove constraint Author: "Ibata, Hidenori"
31 results on '"Ibata, Hidenori"'

Search Results

2. Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors

3. Transforming Lung Cancer Management: A Promising Case Study of Immune Checkpoint Inhibitor Success Following a Multidisciplinary Approach.

4. Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis

5. Next‐generation sequencing clarified why first‐line treatment with osimertinib was ineffective in an autopsied case of EGFR‐mutated lung squamous cell carcinoma

6. Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation

7. Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy

8. Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?

9. Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: A case report

10. Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors inEGFR‐mutated non‐small cell lung cancer patients with T790M ‐negative or unidentified mutation

14. Correlation between increased granulocyte elastase release and activation of blood coagulation in patients with lung cancer

15. Evaluating prethrombotic state in lung cancer using molecular markers

16. Additional file 1: of A randomized phase II study to assess the effect of adjuvant immunotherapy using Îą-GalCer-pulsed dendritic cells in the patients with completely resected stage IIâ IIIA non-small cell lung cancer: study protocol for a randomized controlled trial

18. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II–IIIA non-small cell lung cancer: study protocol for a randomized controlled trial

19. Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

20. Updated overall survival (OS) results of randomized phase III trial of erlotinib (E) versus (v) docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC): Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

21. Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

23. Japanese Journal of Environmental Infections

26. Cooling Sodium Alginate Has Stronger Analgesic Effect with Respect to Adverse Reaction-induced Pain in Radiotherapy

29. Bronchopulmonary Disease in Ulcerative Colitis.

30. Pulmonary Infiltrates and Skin Pigmentation Associated with Sulfasalazine.

Catalog

Books, media, physical & digital resources